Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15500843 | 0.82 | L3MBTL1 (0.48) | ALDH1A1POLBKMT2ATDP1MAPK1 | |
| SCHEMBL1728937 | 0.76 | POLB (0.50) | POLBLMNA | |
| SCHEMBL6252907 | 0.75 | ALDH1A1 (0.53) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL27606338 | 0.73 | PDE4B (0.40) | ALDH1A1KMT2APDE4BLMNA | |
| SCHEMBL3184892 | 0.73 | SIGMAR1 (0.48) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL8419163 | 0.72 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL10666425 | 0.72 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL2321110 | 0.72 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL12302147 | 0.71 | ALDH1A1 (0.46) | ALDH1A1POLBKMT2ATDP1MAPK1 | |
| SCHEMBL12287978 | 0.71 | NOS1 (0.45) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11788080-B2 | Modified cleavases, uses thereof and related kits | Encodia, Inc. (US) | 2023-10-17 | — | — | US | claimed |
| EP-3430000-B1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10822311-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| EP-3430000-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | Afferent Pharmaceuticals Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017160569-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| EP-2488502-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Rib-X Pharmaceuticals, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011044503-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011047323-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011044503-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20080207655-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | ALDH1A1 2023/4885POLB 1948/4885KMT2A 1868/4885 |
| US-10822311-B2 | Pyrimidines and variants thereof, and uses therefor | P2RX3, P2RX5, P2RX4 | ALDH1A1 1586/4885POLB 1896/4885KMT2A 3955/4885 |
| US-20080207655-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | P2RX3, P2RX2, P2RX6 | ALDH1A1 767/4885POLB 2764/4885KMT2A 3592/4885 |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | ALDH1A1 2023/4885POLB 1948/4885KMT2A 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.